Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
EPA CPDat observed this chemical in 118 composition records across product categories including Personal care.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 (low) · high confidence.
Prevalence of SODIUM POLYSTYRENE SULFONATE in our catalog (epa_cpdat).
Products
118
Brands
6
Typical roles
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 118 composition records across product categories including Personal care. EPA CPDat classifies this chemical for functional uses including Surfactant (surface active agent), Film former, Viscosity modifier.
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.25 %v/v
US
FDA
TL Advanced Tightening Neck Cream PLUS
StriVectin
Route: OPHTHALMIC; Dosage form: SUSPENSION/ DROPS; Potency: 0.25 %w/v
US
FDA
Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Potency: 170.4 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Maximum daily exposure: 728 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 518 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 261 mg
US
FDA
Route: ORAL; Dosage form: TABLET, CHEWABLE, EXTENDED RELEASE; Maximum daily exposure: 125 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 73 mg
US
FDA
FDA NDC lists this ingredient in 19 active drug products and 19 total products.